|
Valeant CEO Michael Pearson has come under increasing pressure
as the company's stock plunged from $263.70 on Aug. 5 to below
$80 last week on scrutiny over high price markups for its drugs
and accusations it used a specialty pharmacy, Philidor Rx
Services, to inflate revenue.
Pearson, Chief Financial Officer Robert Rosiello along with
other executives will conduct the call, which will start at 8.00
a.m ET, Valeant said.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Savio
D'Souza)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
